Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ipilimumab

ipilimumab

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ipilimumab

160 trials tracked of ipilimumab: 33 in phase 3 or 4 and 24 with published results. The most-cited published study has 3692 citations.

160Trials tracked
33Phase 3 & 4
0Recruiting
24With published results
Phase distribution
Phase 4 2 Phase 3 31 Phase 2 112 Phase 1 12 Other / NA 3
  1. Phase 3 Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) Completed · 3,692 cited
  2. Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed · 2,828 cited
  3. Phase 3 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Completed · 1,437 cited
  4. Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC Completed · 1,356 cited
  5. Phase 3 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Completed · 1,189 cited
  6. Phase 3 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Completed · 1,168 cited
Show 44 more trials
  1. Phase 3 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed · 535 cited
  2. Phase 3 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed · 493 cited
  3. Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy Completed · 264 cited
  4. Phase 3 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) Completed · 262 cited
  5. Phase 3 Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) Completed · 253 cited
  6. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 212 cited
  7. Phase 3 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Completed · 170 cited
  8. Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) Completed · 162 cited
  9. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma Completed · 157 cited
  10. Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed · 157 cited
  11. Phase 3 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy Completed · 149 cited
  12. Phase 4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer Completed · 137 cited
  13. Phase 3 Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer Completed · 134 cited
  14. Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Completed · 41 cited
  15. Phase 3 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma Completed · 31 cited
  16. Phase 3 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma Completed · 25 cited
  17. Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Completed · 20 cited
  18. Phase 3 A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma Completed
  19. Phase 4 A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India Completed
  20. Phase 3 Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin Completed
  21. Phase 3 Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin Completed
  22. Phase 3 A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine Completed
  23. Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer Completed
  24. Phase 3 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma Completed
  25. Phase 3 Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma Completed
  26. Phase 3 Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) Completed
  27. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer Completed
  28. Phase 2 Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma Completed
  29. Phase 2 A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers Completed
  30. Phase 2 Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 Completed
  31. Phase 2 Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients Completed
  32. Phase 2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma Completed
  33. Phase 2 A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors Completed
  34. Phase 2 A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors Completed
  35. Phase 2 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Completed
  36. Phase 2 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Completed
  37. Phase 2 Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Completed
  38. Phase 2 Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Completed
  39. Phase 2 A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors Completed
  40. Phase 2 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Completed
  41. Phase 2 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer Completed
  42. Phase 2 Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma Completed
  43. Phase 2 Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers Completed
  44. Phase 2 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread Completed

Showing the 50 most-cited and recently-updated of 160 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
Drug Pipeline Meta-analysis
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
Frontiers Jun 13, 2026
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
Oncology Meta-analysis
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
May 22, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial
Oncology RCT
Nivolumab plus ipilimumab versus nivolumab in advanced neuroendocrine carcinoma phase II trial New Combo Shows Modest Promise for Hard-to-Treat Neuroendocrine Cancers
This randomized phase II trial enrolled 185 patients with advanced neuroendocrine carcinoma refractory to platinum-based chemotherapy.
For patients with rare, aggressive neuroendocrine cancers that resist initial treatment, this study offers a new, though modest, combination…
Apr 23, 2026
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
Oncology Cohort
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Frontiers Apr 23, 2026
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Nephrology Cohort
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Frontiers Apr 21, 2026
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
Allergy & Immunology Sys. Review
Narrative review discusses immune checkpoint inhibitors in lung cancer patients New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Frontiers Apr 20, 2026
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy
Diabetes & Endocrinology Sys. Review
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy The Hidden Reason Children's Brain Tumors Respond So Differently to Treatment
This narrative review examines the role of CSF1R inhibitors as precision immunotherapy for pediatric medulloblastoma subtypes.
Each subtype of children's brain tumors has a unique immune fingerprint, meaning matching treatment to that specific environment could drama…
Frontiers Apr 18, 2026
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
Drug Pipeline RCT
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma Low Drug Levels Mean Worse Outcomes
This randomized phase 2 trial evaluated nivolumab and ipilimumab trough plasma concentrations in 110 patients with metastatic clear cell ren…
Low levels of a common kidney cancer drug are linked to worse survival outcomes when used with another powerful medicine.
Apr 18, 2026
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer
Oncology Phase II
Neoadjuvant nivolumab alone or with ipilimumab in cisplatin-ineligible muscle-invasive bladder cancer Hope for Bladder Cancer When Chemo Isn't an Option
This Phase II trial evaluated neoadjuvant nivolumab alone or with ipilimumab in 30 cisplatin-ineligible patients with muscle-invasive bladde…
Patients with advanced bladder cancer who can't take standard chemo may now qualify for surgery after a new immunotherapy treatment.
Apr 16, 2026
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer
Gastroenterology Phase I
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer Who Really Responds to a Stubborn Colon Cancer Combo?
A phase I trial in 29 patients with microsatellite-stable metastatic colorectal cancer tested the combination of regorafenib, ipilimumab, an…
A three-drug combo helped some patients with stubborn colon cancer, and immune markers now predict who will benefit most.
Apr 14, 2026
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab
Oncology Phase II
Larger baseline tumor burden linked to shorter OS in rare cancers treated with nivolumab plus ipilimumab Does tumor size predict how well immunotherapy works for rare cancers?
A secondary analysis of a phase 2 basket trial in 722 patients with rare/ultrarare malignancies found that larger baseline tumor burden was …
For rare cancers treated with immunotherapy, larger tumors at the start were linked to shorter overall survival, but not to how long patient…
Apr 2, 2026

All ipilimumab Articles